Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
09 nov. 2018 10h04 HE
|
Gradalis, Inc.
DALLAS, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
08 nov. 2018 16h44 HE
|
Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
07 nov. 2018 07h00 HE
|
CureVac AG
Data to be presented includes CV8102 as a single agent and in combination with anti-PD1 therapy TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
06 nov. 2018 08h01 HE
|
Sorrento Therapeutics, Inc.
Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standard of care 3 to 6 monthsMeeting...
Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours
05 nov. 2018 09h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
01 nov. 2018 08h30 HE
|
Fluidigm Corporation
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sirona Dx,...
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
01 nov. 2018 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to...
Orion Biotechnology Completes Scientific Advice Meeting with MHRA
31 oct. 2018 11h19 HE
|
Orion Biotechnology Canada Ltd
OTTAWA, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, announced today the completion of a scientific advice meeting with the Medicines...
CrownBio Releases MuBase® 2.0, An Open Access Database of Immuno-Oncology Murine Models
25 oct. 2018 09h15 HE
|
Crown Bioscience
Updates enhance user experience, provide comprehensive characterization data, and add new models SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and...
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
17 oct. 2018 08h30 HE
|
Todos Medical Ltd.
REHOVOT, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early...